20 "Urinary Bladder" clinical trials found.
-
Phase 2b Clinical Study Evaluating Efficacy and Safety of TAR-200 in Combination with Cetrelimab TAR-200 Alone or Cetrelimab Alone in Participants with High-Risk Non- Muscle Invasive Bladder Cancer (NMIBC) Unresponsive to Intravesical Bacillus Calmette-Guerin (BCG) who are Ineligible for or Elected Not to Undergo Radical Cystectomy
The purpose of the study is to determine the efficacy and safety of TAR-200 in combination with Cetrelimab, TAR-200 Alone, or Cetrelimab Alone in participants ... -
A Phase 1/2 Study of EG-70 as an Intravesical Administration to Patients with BCG-Unresponsive NMIBC
The purpose of the study is to evaluate the safety and efficacy of intravesical administration of EG-70 and its effect on bladder tumors in patients ... -
A Multicenter Clinical Trial of Intravesical Bacillus Calmetter-Guerin (BCG) in combination with ALT-803 in Patients with BCG Unresponsive High Grade non-Muscle Invasive Bladder Cancer
The purpose of the study is to assess effectiveness and safety of the intravesical BCG (Bacillus Calmetter-Guerin) in combination with ALT-803 in patients with BCG ... -
A Phase 3 Randomized Comparator-controlled Study of the Efficacy and Safety of Pembro in Comb. with BCG in Participants with HR Non-muscle Invasive Bladder Cancer (HR NMIBC) that is Persistent or Recurrent Following BCG Induction
The purpose of the study is to test the safety of the study drugs, pembrolizumab in combination with Bacillus Calmette-Guerin (BCG) and we want to ... -
Site for 10144 - A Phase II Study of Olaparib (AZD2281) in Patients with Metastatic/Advanced Urothelial Carcinoma with DNA-Repair Defects
The purpose of the study is to determine if olaparib works in treating patients with urothelial cancer with deoxyribonucleic acid (DNA)-repair defects that has ... -
A Phase II Open Label Study of IMMU-132 in Metastatic Urothelial Cancer After Failure of Platinum-Based Regimen or Anti-PD-1 / PD-L1 Based Immunotherapy
If you have been diagnosed with urothelial cancer that has progressed or returned, you may be qualified for this Phase 2 study. The main goal ... -
A Phase 1 First-in Human Multi-Center Open Label Dose-Escalation Study to Determine the Safety Tolerability Pharmacokinetics and RP2D of ABBV-151 as a Single Agent and in Combination with ABBV-181 in Subjects with Locally Advanced or Metastatic Solid Tumors (AbbVie M19-345)
The purpose of the study is to look at safety and efficacy of study drug ABBV-151 alone and in combination with study drug ABBV-181. We ... -
Phase 1/2 Safety and Efficacy Study of NUV-868 as Monotherapy and in Combination With Olaparib or Enzalutamide in Adult Patients With Advanced Solid Tumors
This study is designed for patients diagnosed with advanced solid tumors and is testing a novel epigenetic modifying strategy to restore tumor cell differentiation.
The ...
-
First-in-human open-label dose-escalation trial with expansion cohorts to evaluate safety of GEN1046 in subjects with malignant solid tumors
The purpose of the study is to determine the safety of GEN1046 in patients with malignant solid tumors. GEN1046 is investigational drug in this study ... -
A Phase 1/2 Study of CPI-0209 Monotherapy and in Combination with Other Therapy in Patients with Advanced Solid Tumors
The purpose of the study is to evaluate the safety and tolerability of the study drug CPI-0209 as monotherapy and in combination with irinotecan in ...